Rugo, Hope S; Trédan, Olivier; Ro, Jungsil; Morales, Serafin M; Campone, Mario; Musolino, Antonino; Afonso, Noémia; Ferreira, Marta; Park, Kyong Hwa; Cortes, Javier; Tan, Antoinette R; Blum, Joanne L; Eaton, Lamar; Gause, Christine K; Wang, Zhen; Im, Ellie; Mauro, David J; Jones, Mary Beth; Denker, Andrew; Baselga, José, A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancer, «BREAST CANCER RESEARCH AND TREATMENT», 2017, 165, pp. 601 - 609 [articolo]
Pellegrino, B.; Musolino, A.; Tiseo, M., Anti-PD-1-related cryoglobulinemia during treatment with nivolumab in NSCLC patient, «ANNALS OF ONCOLOGY», 2017, 28, pp. 1405 - 1406 [articolo]
Cicchiello, F.; Riva, F.; Cazzaniga, M. E.; Pedani, F.; Nicolini, M.; Butti, C.; Liscia, N.; Pogliani, C.; Capri, G.; Alu, M.; Febbraro, A.; Petrucelli, L.; D'Onofrio, L.; De Laurentiis, M.; Pellegrini, D.; Mentuccia, L.; Cocciolone, V.; Miraglio, E.; Bajardi, E.; Dester, M.; Paterno, E.; Guaitoli, G.; Ferrarini, I.; Gervasi, E.; Licata, L.; Benedetto, C.; Andreis, D.; Bordin, E.; Ancona, C.; Pizzuti, L.; Fotia, V.; Berardi, R.; Cazzaniga, M. E.; Airoldi, M.; Arcangeli, V.; Artale, S.; Atzori, F.; Ballerio, A.; Bianchi, G. V.; Blasi, L.; Campidoglio, S.; Ciccarese, M.; Cursano, M. C.; Piezzo, M.; Fabi, A.; Ferrari, L.; Ferzi, A.; Ficorella, C.; Frassoldati, A.; Fumagalli, A.; Garrone, O.; Gebbia, V.; Generali, D.; La Verde, N.; Maur, M.; Michelotti, A.; Moretti, G.; Musolino, A.; Palumbo, R.; Pistelli, M.; Porpiglia, M.; Sartori, D.; Scavelli, C.; Schirone, A.; Turletti, A.; Valerio, M. R.; Vici, P.; Zambelli, A.; Clivio, L.; Torri, V., Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2−) advanced breast cancer patients: New insights beyond clinical trials. The EVA study, «THE BREAST», 2017, 35, pp. 115 - 121 [articolo]
Tommasi, C.; Pellegrino, B.; Quaini, F.; Musolino, A., My best choice after a round trip from illness, «ACTA BIO-MEDICA DE L'ATENEO PARMENSE», 2017, 88, pp. 196 - 197 [articolo]
Pellegrino, B.; Boggiani, D.; Tommasi, C.; Palli, D.; Musolino, A., Nab-paclitaxel after docetaxel hypersensitivity reaction: case report and literature review, «ACTA BIO-MEDICA DE L'ATENEO PARMENSE», 2017, 88, pp. 329 - 333 [articolo]
Musolino, A.; Campone, M.; Neven, P.; Denduluri, N.; Barrios, C. H.; Cortes, J.; Blackwell, K.; Soliman, H.; Kahan, Z.; Bonnefoi, H.; Squires, M.; Zhang, Y.; Deudon, S.; Shi, M. M.; Andre, F., Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2- breast cancer that had progressed during or after prior endocrine therapy, «BREAST CANCER RESEARCH», 2017, 19, pp. 1 - 14 [articolo]
Gligorov, J.; Ataseven, B.; Verrill, M.; de Laurentiis, M.; Jung, K. H.; Azim, H. A.; Al-Sakaff, N.; Lauer, S.; Shing, M.; Pivot, X.; Koroveshi, D.; Bouzid, K.; Casalnuovo, M.; Cascallar, D.; Korbenfeld, E. P.; Bastick, P.; Beith, J.; Colosimo, M.; Friedlander, M.; Ganju, V.; Green, M.; Patterson, K.; Redfern, A.; Richardson, G.; Ceric, T.; Gordana, K.; Beato, C. A.; Ferrari, M.; Hegg, R.; Helena, V.; Ismael, G. F.; Lessa, A. E.; Mano, M.; Morelle, A.; Nogueira, J. A.; Timcheva, K.; Tomova, A.; Tsakova, M.; Zlatareva-Petrova, A.; Asselah, J.; Assi, H.; Brezden-Masley, C.; Chia, S.; Freedman, O.; Harb, M.; Joy, A. A.; Kulkarni, S.; Prady, C.; Gaete, A. A. A.; Matamala, L.; Torres, R.; Yanez, E.; Franco, S.; Urrego, M.; Gugic, D.; Vrbanec, D.; Melichar, B.; Prausova, J.; Vyzula, R.; Pilarte, R. G.; Leon, M. I.; Munoz, R.; Ramos, G.; Azeem, H. A.; Aziz, A. A.; El Zawahry, H.; Osegueda, F. R.; Alexandre, J.; Artignan, X.; Barletta, H.; Beguier, E.; Berdah, J. -F.; Marty, C. B.; Bollet, M., Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients, «EUROPEAN JOURNAL OF CANCER», 2017, 82, pp. 237 - 246 [articolo]
Duchnowska, R; Jarząb, M; Żebracka-Gala, J; Matkowski, R; Kowalczyk, A; Radecka, B; Kowalska, M; Pfeifer, A; Foszczyńska-Kłoda, M; Musolino, A; Czartoryska-Arłukowicz, B; Litwiniuk, M; Surus-Hyla, A; Szabłowska-Siwik, S; Karczmarek-Borowska, B; Dębska-Szmich, S; Głodek-Sutek, B; Sosińska-Mielcarek, K; Chmielowska, E; Kalinka-Warzocha, E; Olszewski, Wp; Patera, J; Żawrocki, A; Pliszka, A; Tyszkiewicz, T; Rusinek, D; Oczko-Wojciechowska, M; Jassem, J; Biernat, W; Polish Brain Metastasis, Consortium, Brain Metastasis Prediction by Transcriptomic Profiling in Triple-Negative Breast Cancer, «CLINICAL BREAST CANCER», 2016, 17, pp. 65 - 75 [articolo]
Negri, Fv; Boggiani, D; Rimanti, A; Musolino, A, FCGR, Cetuximab, and Colorectal Cancer Survival-Letter, «CLINICAL CANCER RESEARCH», 2016, 1, pp. 4958 - 4958 [articolo]
Musolino, A; Naldi, N.; Dieci, M. V.; Zanoni, D.; Rimanti, A.; Boggiani, D.; Sgargi, P.; Generali, D. G.; Piacentini, F.; Ambroggi, M.; Cagossi, K.; Gianni, L.; Sarti, S.; Bisagni, G.; Ardizzoni, Andrea; Conte, P. F.; Guarneri, V., Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancer, «PHARMACOGENOMICS JOURNAL», 2016, 16, pp. 472 - 477 [articolo]
Musolino, A; Boggiani, ; D;, Sikokis; A;, Rimanti; A;, Pellegrino; B;, Vattiato; R;, Sgargi; P;, Falcini; F;, Caminiti; C;, Michiara; M;, Leonardi; F,, Prognostic risk factors for treatment decision in pT1a,b N0M0 HER2 positive
breast cancers, «CANCER TREATMENT REVIEWS», 2016, 43, pp. 1 - 7 [articolo]
Pellegrino, ; Bella, ; Michiara, ; Zanelli, ; Naldi, ; Porzio, ; Bortesi, ; Boggiani, ; Zanoni, ; Camisa, ; Neri, ; T., M.; Pinto, ; Musolino, A, Triple negative status and BRCA mutations in contralateral breast cancer: A population-based study, «ACTA BIO-MEDICA DE L'ATENEO PARMENSE», 2016, 6, pp. 54 - 63 [articolo]
Guarneri, V.; Dieci, M. V.; Frassoldati, A.; Maiorana, A.; Ficarra, G.; Bettelli, S.; Tagliafico, E.; Bicciato, S.; Generali, D. G.; Cagossi, K.; Bisagni, G.; Sarti, S.; Musolino, A.; Ellis, C.; Crescenzo, R.; Conte, P., Prospective biomarker analysis of the randomized CHER-LOB study evaluating the dual anti-HER2 treatment with trastuzumab and lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive breast cancer, «THE ONCOLOGIST», 2015, 20, pp. 1001 - 1010 [articolo]
Buti, Sebastiano; Bersanelli, Melissa; Tiseo, Marcello; Ardizzoni, Andrea; Musolino, Antonino, BOLERO-3 results: Pharmacological activity or pharmacokinetic effect?, «THE LANCET ONCOLOGY», 2014, 15, pp. e304 - e304 [articolo]
Negri, F.V; Musolino, A.; Naldi, N.; Bortesi, B.; Missale, G.; Laccabue, D.; Zerbini, A.; Camisa, R.; Chernyschova, N.; Bisagni, G.; Loupakis, F.; Ruzzo, A.; Neri, T.M.; Ardizzoni, A., Role of immunoglobulin G fragment C receptor polymorphism-mediated antibody-dependant cellular cytotoxicity in colorectal cancer treated with cetuximab therapy, «PHARMACOGENOMICS JOURNAL», 2014, 14, pp. 14 - 19 [articolo]
